title: Stem cell therapy for white matter disorders: don't forget the microenvironment!
abstract: White matter disorders (WMDs) are a major source of handicap at all ages. They often lead to progressive neurological dysfunction and early death. Although causes are highly diverse, WMDs share the property that glia (astrocytes and oligodendrocytes) are among the cells primarily affected, and that myelin is either not formed or lost. Many WMDs might benefit from cell replacement therapies. Successful preclinical studies in rodent models have already led to the first clinical trials in humans using glial or oligodendrocyte progenitor cells aiming at (re)myelination. However, myelin is usually not the only affected structure. Neurons, microglia, and astrocytes are often also affected and are all important partners in creating the right conditions for proper white matter repair. Composition of the extracellular environment is another factor to be considered. Cell transplantation therapies might therefore require inclusion of non-oligodendroglial cell types and target more than only myelin repair. WMD patients would likely benefit from multimodal therapy approaches involving stem cell transplantation and microenvironment-targeting strategies to alter the local environment to a more favorable state for cell replacement. Furthermore most proof-of-concept studies have been performed with human cells in rodent disease models. Since human glial cells show a larger regenerative capacity than their mouse counterparts in the host mouse brain, microenvironmental factors affecting white matter recovery might be overlooked in rodent studies. We would like to stress that cell replacement therapy is a highly promising therapeutic option for WMDs, but a receptive microenvironment is crucial.
authors.affiliation: Department of Pediatrics/Child Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Dooves
authors.affiliation: Department of Pediatrics/Child Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.|Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University, Amsterdam, The Netherlands.
authors.forename: Marjo S
authors.initials: MS
authors.lastname: van der Knaap
authors.affiliation: Department of Pediatrics/Child Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. vm.heine@vumc.nl.|Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, VU University, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands. vm.heine@vumc.nl.
authors.forename: Vivi M
authors.initials: VM
authors.lastname: Heine
mesh_terms: D000818:Animals; D001927:Brain Diseases / Q000473:pathology / Q000628:therapy*; D006801:Humans; D051379:Mice; D055153:Stem Cell Niche / Q000502:physiology*; D033581:Stem Cell Transplantation / Q000379:methods*; D066127:White Matter / Q000473:pathology*